Chromosome Disorders  >>  mavoglurant (STP7)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mavoglurant (STP7) / STALICLA
NCT01357239 / 2010-022638-96: Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

Completed
2
139
US, Canada, Europe, RoW
AFQ056, Placebo
Novartis Pharmaceuticals
Fragile X Syndrome
01/14
01/14
NCT01348087 / 2011-001952-12: Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

Terminated
2
148
US, Canada, Europe, RoW
AFQ056
Novartis Pharmaceuticals
Fragile X Syndrome
09/14
09/14

Download Options